LGSOC Drugs: A Guide to Every Treatment Option Available Today

LGSOC drugs have evolved dramatically in recent years, and for patients navigating a low-grade serous ovarian cancer diagnosis, understanding what’s out there can feel like the difference between paralysis and power.

This is a rare cancer. It’s also one that behaves differently from most ovarian cancers, which means it requires a completely different treatment approach. The drugs that work well for high-grade serous ovarian cancer (HGSOC) often don’t work nearly as well here. And for a long time, that left patients with very few options.

That’s changing.

This guide breaks down every major LGSOC drug category: from surgery and chemotherapy to targeted therapies and the first-ever FDA-approved treatment specifically for this disease. We’ll explain how each one works, what the evidence actually says, and what questions you should be asking your doctor.

Why LGSOC Requires Its Own Treatment Playbook

Before diving into the drugs themselves, it helps to understand why LGSOC is treated differently.

Low-grade serous ovarian cancer is a molecularly distinct disease. Unlike HGSOC, which typically involves TP53 mutations and responds well to platinum-based chemotherapy, LGSOC tumors are often driven by mutations (roughly 47 to 60%) in the MAPK signaling pathway, particularly in genes like KRAS, NRAS, and BRAF. 

LGSOC also tends to:

• Strike younger women (median age around 45–48, compared to 63 for HGSOC)
• Grow more slowly but recur at high rates, with over 80% of patients experiencing LGSOC recurrence
• Show relatively poor responsiveness to standard chemotherapy (response rates as low as 4 to 23%, compared to 66 to 90% for HGSOC)
• Express estrogen and progesterone receptors in the majority of cases, making it hormone-sensitive

This biology shapes everything about how LGSOC is treated. The goal is to target the specific molecular drivers that make this cancer grow.

Surgery: The Foundation of LGSOC Treatment

At initial diagnosis, surgery is almost always the first step — before any drug enters the picture.

The extent of surgical resection (how much of the tumor is removed) is one of the strongest predictors of survival in LGSOC. Complete gross resection (no visible remaining disease) is strongly associated with improved outcomes.

Because LGSOC responds so poorly to chemotherapy for many women, surgeons often make maximum efforts to achieve complete removal even when that is technically difficult.

At recurrence, the picture is much less clear-cut. There’s no standard order for which drugs come when, and surgery is no longer an automatic first move. Because LGSOC often returns in scattered spots across the abdomen, removing it completely a second time isn’t always feasible. 

NCCN guidelines suggest considering secondary cytoreductive surgery only for select patients: generally those whose cancer returned more than six months after finishing chemotherapy, who are in good overall health, have no ascites (fluid buildup in the abdomen), and whose disease is confined to a single area that can be fully resected. Even when someone fits that profile, the surgical team still weighs the risks against the likely benefit before operating.

To learn more about what surgical treatment looks like, visit our guide to debulking surgery for ovarian cancer.

Chemotherapy for LGSOC: Necessary, But Limited

Here’s an uncomfortable truth: standard chemotherapy doesn’t work very well for the majority of women diagnosed with LGSOC.

The current first-line standard (carboplatin and paclitaxel) is recommended following surgery, largely because it’s the established backbone for ovarian cancer treatment broadly. But the data specific to LGSOC tells a more nuanced story. One retrospective analysis found an overall response rate of just 23% in LGSOC patients, compared to 66 to 90% in HGSOC patients receiving the same regimen.

In the recurrent setting, the picture stays discouraging. One study found that platinum-based chemotherapy produced an objective response in 22% of patients in the second line and just 10% in the third, with rates continuing to fall in later lines. By contrast, platinum-sensitive high-grade serous ovarian cancer typically responds to further chemotherapy far more often, on the order of 60 to 80%.

The low average, though, doesn’t mean chemotherapy gets written off. It works well for some women. And because there’s still no reliable way to predict in advance who will respond and who won’t, chemo remains a recommended frontline option rather than something to skip. The benefit is real but unevenly distributed, and right now we can’t cleanly identify which patients fall into the group it helps.

So why use it at all? Partly because it’s the standard of care that most guidelines were built around before we understood LGSOC well. Partly because some patients do achieve disease stabilization, even without a formal response. And partly because in the absence of better alternatives at initial diagnosis, it remains a reasonable bridge.

But the field is moving decisively toward targeted therapies, and with good reason.

Hormone Therapy: A Low-Toxicity Option With Meaningful Benefit

Because most LGSOC tumors express estrogen receptors and progesterone receptors, hormonal therapy has become an important part of the treatment landscape, particularly for maintenance and recurrent disease.

In simple terms, this means the cancer cells have receptors that allow hormones like estrogen to attach and signal the cells to grow. Hormone therapy works by either blocking those “docking stations” or reducing the amount of estrogen available, effectively starving the cancer of the fuel it uses to spread.

Aromatase Inhibitors (AIs)

Aromatase inhibitors are among the most commonly used LGSOC drugs in the hormone therapy category. They work by blocking an enzyme called aromatase, which produces estrogen in post-menopausal women (from fat tissue and adrenal glands).

The most frequently used aromatase inhibitors in LGSOC include:

• Letrozole (Femara): 2.5 mg daily; often the first choice.
• Anastrozole (Arimidex): 1 mg daily; considered equally effective.
• Exemestane (Aromasin): 25 mg daily; a steroidal aromatase inhibitor, structurally distinct from the other two. Its side-effect profile is more of a trade-off than a straightforward improvement. In breast cancer studies, it’s been associated with less hypercholesterolemia but more gastrointestinal side effects and a higher rate of diabetes, along with higher discontinuation rates than letrozole or anastrozole. Whether that same pattern holds in LGSOC hasn’t been studied specifically.

The evidence for aromatase inhibitors is largely retrospective, but the takeaway is meaningful: patients who received hormone maintenance therapy lived significantly longer without their cancer progressing than those who didn’t. 

And while formal tumor shrinkage is relatively rare with these drugs, many patients achieve prolonged stable disease: meaning, the cancer simply stops advancing. That matters enormously in a disease where quality of life and time are everything

Tamoxifen: Is It Recommended?

Tamoxifen is a selective estrogen receptor modulator (SERM). Unlike aromatase inhibitors, which lower the body’s estrogen, tamoxifen blocks estrogen at the receptor. 

But it can also act as a partial estrogen agonist, meaning that in some tissues it mimics estrogen instead of blocking it. That’s the problem in LGSOC: there’s a theoretical concern that this partial agonist activity could actually stimulate an estrogen receptor–positive tumor rather than suppress it.

For that reason, NCCN guidelines no longer list tamoxifen as a recommended hormonal therapy for LGSOC. The limited head-to-head data point the same direction. In the GOG 281 trial, among patients who received hormone therapy, those on letrozole had a 14% response rate compared to 0% for those on tamoxifen, though the trial wasn’t designed to compare the two directly.

Fulvestrant

Fulvestrant (Faslodex) is a selective estrogen receptor degrader (SERD). Rather than just blocking estrogen receptors, it binds to them and breaks them down entirely. It’s given as an intramuscular injection.

Fulvestrant does have a place in the NCCN hormonal therapy options for LGSOC, with a specific role at recurrence, particularly for patients who’ve already been treated with an aromatase inhibitor. 

The direct evidence is limited, but a phase II trial in recurrent epithelial ovarian cancer (not LGSOC specifically) found that 50% of patients achieved stable disease. That reinforces the broader pattern across hormone therapies in this setting: outright tumor shrinkage is uncommon, but holding the cancer steady is a realistic and meaningful goal. Fulvestrant has also been studied in combination with CDK4/6 inhibitors. (More on this below.) 

MEK Inhibitors: Targeting the MAPK Pathway

This is where LGSOC treatment starts to diverge meaningfully from standard ovarian cancer care.

Because so many LGSOC tumors carry mutations that activate the MAPK signaling pathway, drugs that block a key protein in this pathway (called MEK) have been studied extensively in LGSOC.

Trametinib (Mekinist) has the strongest evidence of any MEK inhibitor studied in LGSOC. The landmark GOG 281/LOGS trial was the first positive randomized trial ever conducted specifically in LGSOC. It established trametinib as a genuine standard-of-care option for recurrent disease. 

Crucially, the progression-free survival benefit held up regardless of whether patients’ tumors carried a KRAS, BRAF, or NRAS mutation. Response rates were a different story, though: about 50% of patients with one of these MAPK pathway mutations saw meaningful tumor shrinkage, compared to roughly 8% of those without. 

Even so, the trial’s authors concluded that trametinib is worth considering for recurrent LGSOC regardless of mutation status, since the survival benefit didn’t hinge on it.

Side effects — including skin rash, high blood pressure, and diarrhea — can be significant and require careful monitoring. But for many patients, the trade-off is worth it. 

Binimetinib (Mektovi) is another MEK inhibitor that has been studied in LGSOC, with more mixed results. It remains in NCCN guidelines as an option, but does not yet have the same level of evidence as trametinib.

Read more: “BRAF and MEK Inhibitors: A Targeted Approach for Low-Grade Serous Ovarian Cancer”

Avutometinib + Defactinib: The First FDA-Approved LGSOC Drug

This is the biggest development in LGSOC treatment in years. 

In May 2025, the FDA granted accelerated approval to the combination of avutometinib (Avmapki) and defactinib (Fakzynja), marketed together as Avmapki Fakzynja Co-Pack, for adult patients with recurrent LGSOC who have a confirmed KRAS mutation and have received prior systemic therapy.

This was a landmark moment. For the first time, there was an FDA-approved treatment specifically designed for LGSOC.

It’s worth understanding the type of approval, though: this was an accelerated approval, which the FDA grants based on early promising results. It’s contingent on a confirmatory trial (RAMP 301) verifying the clinical benefit before the approval becomes permanent.

How It Works

Standard MEK inhibitors often lose effectiveness over time because cancer cells find workarounds. The avutometinib + defactinib combination is designed to block two escape routes simultaneously. 

Here’s the difference. A standard MEK inhibitor blocks MEK, but cancer cells fight back. The protein sitting just above MEK in the pathway (called RAF) simply switches MEK back on, reigniting the signal and driving resistance. 

Avutometinib binds differently. It acts as a RAF/MEK “clamp,” locking MEK in an inactive shape and stopping RAF from flipping it back on, so the pathway stays shut down instead of rebounding. Defactinib, meanwhile, blocks a separate backup survival route that cancer cells lean on when the main pathway is cut off. Together, they work like a double lock.

What the Evidence Shows

The FDA approval was based on the Phase 2 RAMP 201 trial, which enrolled patients with recurrent LGSOC both with and without a KRAS mutation. 

Across the whole group, 31% of patients saw meaningful tumor shrinkage. But among the KRAS-mutated patients, the group the approval actually covers, that figure climbed to 44%, nearly half. Either number is striking next to the low response rates typical of chemotherapy in this disease. The responses also proved durable, lasting a median of more than two and a half years, and only about 10% of patients stopped treatment because of side effects.

CDK4/6 Inhibitors: A Promising Emerging Option

CDK4/6 inhibitors are a class of drugs that work differently from MEK inhibitors. They block proteins (cyclin-dependent kinases 4 and 6) that cancer cells use to progress through the cell division cycle. They’re already well-established in hormone receptor–positive breast cancer, and there’s growing evidence they may help in LGSOC, too.

This makes biological sense. LGSOC tumors often lose expression of p16, a protein that normally acts as a brake on CDK4/6 activity. Take that brake away, and CDK4/6 runs unchecked, pushing cells through the division cycle without the usual restraint. That’s exactly the pathway these drugs are built to block.

Ribociclib + Letrozole (GOG 3026)

The most promising CDK4/6 inhibitor data in LGSOC comes from combining ribociclib with the aromatase inhibitor letrozole. 

Results from the GOG 3026 trial were encouraging. Notably, responses kept improving over time, which reflects how slowly but steadily LGSOC tends to respond to non-chemotherapy treatments. 

Abemaciclib + Fulvestrant

One study tested abemaciclib combined with fulvestrant before surgery in patients with advanced, inoperable LGSOC. The results were striking enough to fuel real interest in researching (in a larger study population) CDK4/6 inhibitors as a pre-surgical option: something that could potentially make more patients eligible for complete tumor removal.

Overall, CDK4/6 inhibitors are not yet FDA-approved for LGSOC. But the early data is promising, and several trials are actively enrolling. If you’re in the recurrent setting and have exhausted other options, ask your oncologist whether ovarian cancer clinical trials involving this drug class might be right for you.

Bevacizumab: An Anti-Angiogenic Option

Bevacizumab (Avastin) is a monoclonal antibody that targets VEGF, a protein that tumors use to grow new blood vessels. It’s included in NCCN guidelines for LGSOC and can be used in both the frontline setting (combined with chemotherapy) and the recurrent setting.

The evidence in LGSOC specifically is largely retrospective, but some studies have found meaningful clinical benefit. Research found a 47.5% objective response rate with bevacizumab-containing regimens, though that figure needs context. 

It reflects bevacizumab used in the recurrent setting, in combination with chemotherapy, not given on its own or as part of primary treatment. Its added value in the frontline setting is much less established.

Bevacizumab also carries real risks, including hypertension, gastrointestinal perforation, blood clots, and proteinuria (the presence of excess protein in the urine). And the survival benefit in LGSOC specifically hasn’t been definitively established in prospective trials.

It remains a reasonable option for some patients, particularly those who have progressed on other therapies.

Emerging LGSOC Drugs: What’s in the Pipeline

Research into LGSOC drugs is accelerating. Here are some of the most relevant active directions:

Can endocrine therapy replace chemotherapy? For years, a major open question in LGSOC was whether hormone therapy alone could stand in for chemotherapy as the first treatment after surgery, sparing patients the side effects. The Phase 3 NRG-GY019 trial was built to answer it, randomizing 450 newly diagnosed patients to either carboplatin/paclitaxel followed by letrozole, or letrozole alone. 

The results were decisive: letrozole on its own did not prove non-inferior. At 12 months, 91% of patients on the chemotherapy-plus-letrozole arm were progression-free, compared to 80% on letrozole alone: a gap wide enough that the trial was stopped early for futility.

Chemotherapy did come at a cost: patients in that arm were about four times more likely to experience a serious (grade 3–4) side effect during the first six cycles. But the takeaway reshaped the frontline conversation. 

Rather than letting patients skip chemo, NRG-GY019 established carboplatin/paclitaxel followed by letrozole as the first definitive standard of care for newly diagnosed advanced LGSOC. This underscored, once again, that chemotherapy still earns its place here for many women.

RAMP 301 (Phase 3 avutometinib + defactinib). The confirmatory Phase 3 trial comparing avutometinib + defactinib to physician’s choice of treatment in all recurrent LGSOC patients — regardless of KRAS status — is ongoing. Results from this trial will determine whether the FDA approval becomes permanent, and whether the treatment can be expanded beyond KRAS-mutated patients.

The RESOLVE trial (abemaciclib + letrozole, with a metformin twist). This Phase 2 study builds on the CDK4/6-plus-hormone-therapy strategy described earlier and asks whether adding a third agent sharpens it. 

Everyone receives abemaciclib (a CDK4/6 inhibitor) plus letrozole; separate cohorts then add metformin, zotatifin, or gedatolisib. The metformin arm is the intriguing one. Metformin is a common, inexpensive diabetes medication being repurposed here for its potential anti-cancer effects — a real-world example of the drug repurposing strategy gaining ground in LGSOC. 

The trial enrolls both low-grade serous ovarian cancer and ER-positive endometrial cancer; early signals from the endometrial side have been encouraging, with LGSOC-specific results still maturing.

Novel biomarker-driven approaches. The BOUQUET trial (NCT04931342) is a Phase 2 basket study testing multiple targeted therapy arms based on specific molecular alterations, moving LGSOC care further toward individualized treatment.

Regorafenib plus fulvestrant. This is one of the few Phase 2 trials testing a combination built specifically for LGSOC, rather than borrowed from another cancer. It pairs fulvestrant — the estrogen receptor degrader discussed earlier — with regorafenib, a drug that blocks several of the growth and blood-vessel signals tumors depend on. 

The goal is to hit the cancer’s hormone dependence and its growth signaling at once, in patients whose disease has returned.

CAR T-cell therapy. At the most experimental edge, a Phase 1 trial at Stanford is testing CAR T-cell therapy, a form of immunotherapy that re-engineers a patient’s own immune cells to recognize and attack tumors in recurrent, platinum-resistant ovarian cancer. 

The scope is worth being clear about: this trial isn’t limited to LGSOC (it accepts several ovarian cancer types), it requires at least one prior platinum-based chemotherapy, and as an early-phase study its first job is to establish safety and dosing, not to prove it works.

Genetic Testing: The Key That Unlocks Better LGSOC Drug Options

If there’s one thing this guide makes clear, it’s this: molecular testing matters enormously in LGSOC.

Knowing whether your tumor carries a KRAS mutation determines whether you qualify for the only FDA-approved LGSOC-specific treatment. Understanding your tumor’s full molecular profile (KRAS, NRAS, BRAF, TP53, and others) helps your oncologist match you to the best available option and identify potential clinical trial eligibility.

Somatic tumor testing (testing the tumor tissue itself, not just a blood test) is the recommended approach. Ask specifically about next-generation sequencing (NGS) panels if you haven’t had one. For more, read our guide to genetic testing for LGSOC.

Asking the Right Questions About Your LGSOC Drug Options

If you’ve just been diagnosed or have experienced a recurrence, here are the questions worth bringing to your next appointment:

• Has my tumor been tested for KRAS, NRAS, BRAF, and other MAPK pathway mutations?
• Based on my molecular profile, which targeted therapies might I qualify for?
• Am I eligible for the avutometinib + defactinib combination?
• Should hormone therapy (like letrozole or anastrozole) be part of my treatment plan?
• Are there any clinical trials currently enrolling that I should consider?
• What is the goal of the treatment you’re recommending — response, stabilization, or something else?

The Bottom Line on LGSOC Drugs

LGSOC has historically been an underserved and under-researched cancer. But the treatment landscape is genuinely shifting faster than many people realize.

The FDA approval of avutometinib and defactinib in 2025 was a historic milestone. More treatments are coming. Clinical trials are actively enrolling. And researchers are getting better at matching treatments to the specific molecular characteristics of each patient’s tumor.